March 11, 2002
Lilly's Evista Reduces Risk of Heart Disease Eli Lilly and Company in the US announced via its Japanese subsidiary, Eli Lilly Japan K.K., that a clinical trial on Evista (raloxifene HCl), a drug approved to prevent and treat osteoporosis in...read more